Your browser doesn't support javascript.
loading
Combination therapy with olaparib and abiraterone acetate for metastatic castration-resistant prostate cancer.
Martini, Alberto; Fallara, Giuseppe; Ploussard, Guillaume; Malavaud, Bernard.
Affiliation
  • Martini A; Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: amartini@mdanderson.org.
  • Fallara G; Department of Urology, European Institute of Oncology Milan, Italy.
  • Ploussard G; Department of Urology, La Croix du Sud Hospital, Toulouse, France; Department of Urology, Institut Universitaire du Cancer Toulouse-Oncopôle, Toulouse, France.
  • Malavaud B; Department of Urology, La Croix du Sud Hospital, Toulouse, France; Department of Urology, Institut Universitaire du Cancer Toulouse-Oncopôle, Toulouse, France.
Lancet Oncol ; 24(10): 1056-1057, 2023 10.
Article in En | MEDLINE | ID: mdl-37797626
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant / Abiraterone Acetate Limits: Humans / Male Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant / Abiraterone Acetate Limits: Humans / Male Language: En Journal: Lancet Oncol Journal subject: NEOPLASIAS Year: 2023 Type: Article